Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 18, 2016

Gyros AB and Protein Technologies Merge to Form Gyros Protein Technologies AB

The merger creates a provider of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and manufacturing.

The merger creates a provider of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and manufacturing.

Gyros AB and Protein Technologies announced on March 16, 2016 that the companies have entered into a definitive merger agreement to form Gyros Protein Technologies AB. The merger is expected to be complete by mid-April 2016 and is subject to certain closing conditions.

Gyros Protein Technologies combines Gyros’ microfluidics, systems development, and immunoassay knowledge with Protein Technologies’ insight in developing and manufacturing instruments for peptide synthesis. The new company will provide a range of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and bioprocessing. According to a press announcement from the company, Gyros Protein Technologies will be led by Dan Calvo as CEO (currently CEO of Gyros AB) and Erik Wiberg as CFO (currently CFO of Protein Technologies).

Source: Gyros AB


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.